About Balanced Kush

Balanced Kush comes from the legendary ‘Hindu Kush’. Hindu Kush is an indica cannabis strain. Offering a sweet wood like smell. the buds give off forest green leaves with light orange pistils.

Australian Bred, Indian Genetics

Balanced Kush Cannabis Strain is a newly cultivated cannabis strain. Therefore, not a lot of information is actually released to the public. However, what we do know is that Balanced Kush comes from the legendary ‘Hindu Kush’. Hindu Kush is an indica cannabis strain. Offering a sweet wood like smell. the buds give off forest green leaves with light orange pistils. The unique part of the strain is the thick layer of trichomes. This is because cultivating Hindu Kush began in Pakistan and Afghanistan. The countries harsh climate gives the cannabis strain its own unique features.

The THC content ranges in the mid levels of 20%. Giving you a euphoric high while giving the consumer pain relief by alleviating tension. Taking your mind off whatever pain is in your body. its relaxing effects will aid people to sleep.

Description provided by Cannabis Strains Australia.

Information provided could come from a third-party source, and likely does not accurately reflect characteristics of the medication we're associating it with - we primarily provide these descriptions for those interested in strain lineage and history, which could also be inaccurate. Any information which could be taken as medical advice should be strictly disregarded. Please consult your doctor regarding the suitability of medications for your condition(s).

About Lyphe Group Ltd

From Lyphe Group, a range of medical flowers and oils focused on giving doctors reassurance in the efficiency and consistency of our supply chain, while providing quality pharmaceutical-grade medication.

At Lyphe our vertical operations span product manufacturing, clinical care, pharmacy dispensing and doctor education. Our direct-to-patient and technology-led approach has quickly established us as the market’s largest player, with a 30% share of all patients. We have also recently entered the Australian market, where we intend to replicate our model of success.

lyphegroup.com